Antibacterial and Biofilm-Targeting Performance of Cefuroxime Axetil-Loaded Eudragit® Nanoparticles

Background/Objectives: Cefuroxime axetil (CA) is a poorly water-soluble second-generation cephalosporin. This study aimed to develop CA-loaded Eudragit® RS100/RL100 nanoparticles (NPs) and investigate the influence of polymer composition and drug-to-polymer ratio on their physicochemical, antibacterial, and antibiofilm properties. Methods: Six CA-loaded NPs (NP-1–NP-6) were prepared using nano spray drying with Eudragit® RS100, RL100, or their 1:1 mixture at drug-to-polymer ratios of 1:1 and 1:2. Particle characteristics, drug content, and structural properties were evaluated. Antibacterial activity was assessed using agar well diffusion, broth microdilution, and time-kill assays, while antibiofilm activity against pre-established Staphylococcus aureus and Escherichia coli biofilms was determined using crystal violet staining. Additional analyses included drug-content-normalized MIC, MIC-normalized time-kill exposure, and concentration–response area under the curve (AUC). Results: All drug-loaded NPs retained antibacterial activity and reduced established biofilm biomass, whereas blank NPs showed no detectable activity. FT-IR and 1H-NMR analyses indicated no evidence of new covalent interactions. Free CA exhibited greater planktonic antibacterial potency, including after drug-content normalization. Among the NPs, NP-1 showed the most favorable MIC profile, while MIC-normalized time-kill analysis revealed NP-dependent exposure differences without consistent bactericidal activity. At 500 µg/mL, all CA-loaded NPs reduced biofilm biomass by more than 95% against both bacterial species. NP-6 exhibited the highest numerical antibiofilm AUC values against S. aureus (133.37) and E. coli (128.85), although these differences were descriptive and did not establish statistical superiority. Conclusions: CA-loaded Eudragit® NPs demonstrated formulation-dependent antibacterial and antibiofilm responses, with NP-1 performing favorably in planktonic inhibition and NP-6 in integrated biofilm biomass reduction. These findings support further investigation of Eudragit®-based antibiotic delivery systems, although superiority over free CA and therapeutic advantages remain unverified.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2026-11-12
DOI
https://doi.org/10.3390/antibiotics15111130
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antibacterial and Biofilm-Targeting Performance of Cefuroxime Axetil-Loaded Eudragit® Nanoparticles

Pervin Soyer, Umay Merve Güven, A. Alper Öztürk, Tilbe Çevikelli
Antibiotics
Advanced Drug Delivery Systems
article

Antibacterial and Biofilm-Targeting Performance of Cefuroxime Axetil-Loaded Eudragit® Nanoparticles

Pervin Soyer, Umay Merve Güven, A. Alper Öztürk, Tilbe Çevikelli
article en

Abstract

Background/Objectives: Cefuroxime axetil (CA) is a poorly water-soluble second-generation cephalosporin. This study aimed to develop CA-loaded Eudragit® RS100/RL100 nanoparticles (NPs) and investigate the influence of polymer composition and drug-to-polymer ratio on their physicochemical, antibacterial, and antibiofilm properties. Methods: Six CA-loaded NPs (NP-1–NP-6) were prepared using nano spray drying with Eudragit® RS100, RL100, or their 1:1 mixture at drug-to-polymer ratios of 1:1 and 1:2. Particle characteristics, drug content, and structural properties were evaluated. Antibacterial activity was assessed using agar well diffusion, broth microdilution, and time-kill assays, while antibiofilm activity against pre-established Staphylococcus aureus and Escherichia coli biofilms was determined using crystal violet staining. Additional analyses included drug-content-normalized MIC, MIC-normalized time-kill exposure, and concentration–response area under the curve (AUC). Results: All drug-loaded NPs retained antibacterial activity and reduced established biofilm biomass, whereas blank NPs showed no detectable activity. FT-IR and 1H-NMR analyses indicated no evidence of new covalent interactions. Free CA exhibited greater planktonic antibacterial potency, including after drug-content normalization. Among the NPs, NP-1 showed the most favorable MIC profile, while MIC-normalized time-kill analysis revealed NP-dependent exposure differences without consistent bactericidal activity. At 500 µg/mL, all CA-loaded NPs reduced biofilm biomass by more than 95% against both bacterial species. NP-6 exhibited the highest numerical antibiofilm AUC values against S. aureus (133.37) and E. coli (128.85), although these differences were descriptive and did not establish statistical superiority. Conclusions: CA-loaded Eudragit® NPs demonstrated formulation-dependent antibacterial and antibiofilm responses, with NP-1 performing favorably in planktonic inhibition and NP-6 in integrated biofilm biomass reduction. These findings support further investigation of Eudragit®-based antibiotic delivery systems, although superiority over free CA and therapeutic advantages remain unverified.

AntibioticsVol. 15(11)
Bahçeşehir University (TR), Anadolu University (TR), Cukurova University (TR)
Anadolu Üniversitesi
Good health and well-being
Advanced Drug Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon